Tau Aggregate Disaggregation via Multi-Functional Heterocyclic Compounds
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapeutic approaches for treating Alzheimer's disease and other tauopathies are limited, with few targeting Tau protein effectively, especially intracellular Tau aggregates, and there is a need for compounds that can recognize and disaggregate Tau aggregates or prevent their formation.
Innovation Solution
Development of novel compounds of formula (I) that can recognize and disaggregate Tau aggregates, prevent their formation, interfere intracellularly with Tau aggregates, reduce Tau misfolding and hyperphosphorylation, and decrease neuroinflammatory markers, thereby addressing the limitations of existing treatments.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If current therapeutic approaches are used for treating Alzheimer's disease, then treatment of amyloid plaques is addressed, but Tau aggregates including intracellular neurofibrillary tangles are not effectively targeted
Solution Approach 1:
The compound is designed to perform multiple functions: it can bind to both amyloid-beta and Tau proteins, addressing both major pathological features of Alzheimer's disease. The molecule contains structural elements that enable interaction with different protein aggregates, making it a universal therapeutic agent against multiple neurodegenerative pathologies simultaneously.
Solution Approach 2:
The compound structure is divided into distinct functional segments: a core heterocyclic structure that provides binding affinity, substituent groups that enable specific interactions with Tau aggregates, and pharmacophoric elements that facilitate blood-brain barrier penetration. This segmentation allows optimization of each function independently while maintaining overall efficacy.
2Ease of operation
If existing treatments focus on extracellular amyloid-beta, then amyloid plaque reduction is achieved, but intracellular Tau aggregate disaggregation is not accomplished
Solution Approach 1:
The compound exhibits different binding properties in different cellular compartments. The molecular structure contains regions that preferentially interact with extracellular amyloid-beta while other regions are optimized for intracellular Tau aggregate binding. This local quality differentiation enables the single compound to effectively target both extracellular and intracellular pathological deposits with appropriate affinity and selectivity.
3Reliability
If novel compounds are developed to target Tau aggregates, then Tau disaggregation capability is improved, but therapeutic complexity increases
Solution Approach 1:
The compound represents a composite molecular structure combining multiple pharmacophoric elements into a single integrated molecule. It incorporates heterocyclic cores, aromatic substituents, and flexible linkers that work synergistically to achieve Tau aggregate binding, disaggregation, and oral bioavailability. This composite approach consolidates multiple functional requirements into one molecule rather than requiring combination therapy.
Data Source
AI summary
The present invention relates to novel compounds that can be employed in the treatment, alleviation or prevention of a group of disorders and abnormalities associated with Tau (Tubulin associated unit) protein aggregates including, but not limited to, Neurofibrillary Tangles (NFTs), such as Alzheimer's disease (AD).